Equities analysts predict that Petmed Express Inc (NASDAQ:PETS) will post earnings of $0.43 per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Petmed Express’ earnings. Petmed Express posted earnings per share of $0.37 in the same quarter last year, which would suggest a positive year-over-year growth rate of 16.2%. The company is expected to report its next quarterly earnings report on Monday, May 14th.
On average, analysts expect that Petmed Express will report full-year earnings of $1.70 per share for the current year, with EPS estimates ranging from $1.64 to $1.76. For the next year, analysts anticipate that the firm will report earnings of $1.94 per share, with EPS estimates ranging from $1.73 to $2.14. Zacks’ EPS calculations are an average based on a survey of research firms that follow Petmed Express.
Petmed Express (NASDAQ:PETS) last posted its earnings results on Monday, January 22nd. The company reported $0.44 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.33 by $0.11. Petmed Express had a net margin of 12.84% and a return on equity of 34.04%. The firm had revenue of $60.10 million during the quarter, compared to analyst estimates of $56.76 million. During the same quarter in the prior year, the business posted $0.24 EPS. The business’s revenue was up 13.6% compared to the same quarter last year.
Several research firms have recently issued reports on PETS. ValuEngine upgraded shares of Petmed Express from a “hold” rating to a “buy” rating in a research note on Wednesday, February 7th. Northcoast Research set a $58.00 target price on shares of Petmed Express and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. BidaskClub lowered shares of Petmed Express from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 19th. Finally, Noble Financial restated a “hold” rating on shares of Petmed Express in a research report on Friday, October 27th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $42.80.
Petmed Express (PETS) traded up $1.52 during midday trading on Thursday, hitting $45.69. 656,956 shares of the stock traded hands, compared to its average volume of 837,624. Petmed Express has a 12-month low of $19.21 and a 12-month high of $57.80. The company has a market cap of $941.26, a price-to-earnings ratio of 27.04, a price-to-earnings-growth ratio of 2.60 and a beta of 0.95.
The business also recently declared a quarterly dividend, which was paid on Friday, February 16th. Investors of record on Monday, February 5th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Friday, February 2nd. This represents a $1.00 annualized dividend and a yield of 2.19%. This is a positive change from Petmed Express’s previous quarterly dividend of $0.20. Petmed Express’s dividend payout ratio is presently 59.17%.
In related news, CEO Menderes Akdag sold 30,000 shares of the stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $51.00, for a total transaction of $1,530,000.00. Following the completion of the transaction, the chief executive officer now owns 490,000 shares in the company, valued at $24,990,000. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Ronald J. Korn sold 5,000 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $48.38, for a total transaction of $241,900.00. Following the transaction, the director now owns 68,833 shares of the company’s stock, valued at approximately $3,330,140.54. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 65,000 shares of company stock valued at $3,229,500. 4.00% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. MetLife Investment Advisors LLC bought a new position in Petmed Express during the fourth quarter valued at about $429,000. BB&T Securities LLC bought a new position in Petmed Express during the fourth quarter worth about $254,000. Municipal Employees Retirement System of Michigan boosted its position in Petmed Express by 23.5% during the fourth quarter. Municipal Employees Retirement System of Michigan now owns 20,790 shares of the company’s stock worth $945,000 after purchasing an additional 3,960 shares during the period. LPL Financial LLC bought a new position in Petmed Express during the fourth quarter worth about $238,000. Finally, PEAK6 Investments L.P. bought a new position in Petmed Express during the fourth quarter worth about $439,000. Institutional investors own 92.01% of the company’s stock.
Petmed Express Company Profile
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.